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Abstract:  In  this  study,  solution  enhanced  dispersion  by  supercritical  fluids  (SEDS) 
technique  was  applied  for  the  preparation  of  5-aminosalicylic  acid  (5-ASA)  loaded 
Eudragit S100 (EU S100) nanoparticles. The effects of various process variables including 
pressure, temperature, 5-ASA concentration and solution flow rate on morphology, particle 
size, 5-ASA loading and entrapment efficiency of nanoparticles were investigated. Under 
the appropriate conditions, drug-loaded nanoparticles exhibited a spherical shape and small 
particle size with narrow particle size distribution. In addition, the nanoparticles prepared 
were  characterized  by  X-ray  diffraction,  Differential  scanning  calorimetry  and  Fourier 
transform infrared spectroscopy analyses. The results showed that 5-ASA was imbedded 
into EU S100 in an amorphous state after SEDS processing and the SEDS process did not 
induce degradation of 5-ASA. 
Keywords: supercritical antisolvent; solution enhanced dispersion by supercritical fluids; 
Eudragit S100; 5-ASA; nanoparticles; colon-specific 
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1. Introduction 
Colon-specific drug delivery system can be applied in many therapeutic areas, especially in the 
treatment of inflammatory bowel disease (IBD) [1–4], which is characterized by recurrent, idiopathic 
inflammatory  disorders  involving  the  mucosa  and  submucosa  of  the  colon.  5-aminosalicylic  acid  
(5-ASA), a typical anti-inflammatory drug, has been used for over 30 years in the treatment of IBD. 
After  the  oral  administration  of  free  5-ASA,  it  is  readily  absorbed  in  the  upper  part  of  the 
gastrointestinal tract and then extensively metabolized to N-acetyl-5-ASA which is inactive in treating 
IBD [5,6]. The clinical efficacy of 5-ASA depends on sufficient therapeutical concentration of the drug 
at the site of the colon mucosa. Therefore, it is preferable for treatment of IBD to deliver the 5-ASA 
specifically to the colon. 
Although many efforts have been made for a higher specificity of entrapped active compounds 
release by designing new drug delivery devices for the treatment of IBD [7,8], all marketed delivery 
systems still appear to be insufficiently selective [9]. This is mainly due to the fact that the drug release 
mechanisms  are  based  on  physiological  parameters  such  as  pH,  bacterial  and  time  which  are  not 
related to the inflammation and barely to its location [6,9,10]. Nanoparticles have shown their specific 
accumulation in the inflamed tissues in the colon. The accumulation phenomenon of nanoparticles is 
observed to be particle size dependent with an increased adhesiveness for smaller particle diameters [11], 
which may therefore allow a selective delivery to the site of inflammation for the treatment of IBD. 
Indeed, nanoparticles showed promising results and demonstrated their therapeutic potential [6,10,12–15].  
Recently,  the  application  of  supercritical  antisolvent  (SAS)  technique  in  the  field  of  particle 
formation, encapsulation and impregnation has received increasing attention, and is anticipated to become 
a very attractive alternative to many conventional processes [16–19]. Compared with most traditional 
processes,  such  as  milling,  spray-drying,  recrystallization  using  solvent  evaporation  and  liquid 
antisolvents, the SAS technique has major advantages because of its lower residual solvents, simpler 
steps and mild operation temperatures. Besides, encapsulation by means of supercritical fluid is of 
great advantage because of its ability to produce uniform particle size and controlled morphology [16]. 
Solution enhanced dispersion by supercritical fluids (SEDS) is one of the SAS processes, which was 
developed to achieve small droplet size and intense mixing of supercritical fluids with solution for 
increasing mass transfer rate at the interface via coaxial nozzle [20].  
The objective of this study was to prepare the 5-ASA loaded colon-specific nanoparticles using  
pH-sensitive polymer Eudragit S100 (EU S100) via SEDS technique and to study the effects of various 
process parameters on the morphology, particle size, 5-ASA loading and entrapment efficiency of 
nanoparticles. EU S100 is an anionic copolymer based on methacrylic acid and methyl methacrylate 
(1:2 ratio). It is insoluble in acids and pure water, whereas soluble in aqueous solution at pH 7 or 
higher. When used to entrap 5-ASA, it is expected to protect 5-ASA from degradation and allow it to 
be released in the region of colon. Moreover, the nanoparticles obtained were characterized by Scanning 
electron microscopy (SEM), Laser particle size analyzer, High efficiency liquid chromatography (HPLC), 
X-ray diffraction (XRD), Differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR) 
spectroscopy. 
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2. Results and Discussion 
2.1. Effect of Process Parameters 
In all trials, the mixed organic solvents of acetone and DMSO (7:3, v/v) were used as dissolvent of 
5-ASA and EU S100. Commonly, a critical factor in the SEDS process is the selection of appropriate 
organic solvent for nanoparticle preparation. 5-ASA, a hydrophilic compound, is mostly insoluble in 
most of organic solvents.  Supercritical fluid  miscible organic solvents  such as  dimethyl  sulfoxide 
(DMSO)  are  suitable  for  dissolving  these  hydrophilic  compounds  [16].  The  choice  of  acetone  is 
rational as it served as the solvent for EU S100, and has always been used for nanoparticle preparation 
via SAS process [21–23]. The determination of the ratio between DMSO and acetone was based on the 
following principles: at first, the organic solvent with high volatility which can induce high volume of 
expansion and can easily be removed from the system should be selected; the solubility of the polymer 
in  the  organic  solvent  should  be  higher  than  that  of  the  drug  in  the  solvent,  which  favors  first 
precipitates of the drug, then drug is coated by the polymer, and finally drug encapsulation by the 
polymer occurs [16]. Both principles favors for a large proportion of acetone to DMSO. Therefore, the 
mixed solvents of acetone and DMSO (7:3, v/v) were used as the organic solution in SEDS process 
through the preliminary experiments (data not shown).  
The experimental conditions and part results were summarized in Table 1, from which it can be 
seen that the process parameters had impact on the morphology, mean particle size, 5-ASA loading 
and entrapment efficiency.  
Table  1.  Experiment  conditions  and  partial  results  of  solution  enhanced  dispersion  by 
supercritical fluids (SEDS) process. 
Pressure 
MPa 
Temperature 
°C  
5-ASA 
concentration 
mg/mL 
Solution 
flow rate 
mL/min 
5-ASA 
loading % 
a 
Entrapment 
efficiency % 
a 
Mean particle 
size nm 
a 
Span 
a 
8  35  1.0  1.0  12.78 ±  0.28  18.90 ±  1.20  395 ±  89  1.98 ±  0.25 
10  35  1.0  1.0  13.06 ±  0.86  37.26 ±  0.98  192 ±  30  1.05 ±  0.12 
12  35  1.0  1.0  7.21 ±  0.26  47.93 ±  1.36  159 ±  22  0.81 ±  0.05 
15  35  1.0  1.0  3.35 ±  0.21  51.12 ±  1.85  147 ±  16  0.62 ±  0.05 
12  40  1.0  1.0  6.20 ±  0.08  46.63 ±  0.48  169 ±  26  1.14 ±  0.93 
12  45  1.0  1.0  4.16 ±  0.35  30.36 ±  0.35  aggregated  - 
12  35  0.5  1.0  3.49 ±  0.08  60.51 ±  0.21  137 ±  20  0.67 ±  0.04 
12  35  1.3  1.0.  9.87 ±  0.35  36.45 ±  1.24  257 ±  40  1.83 ±  0.20 
12  35  1.0  0.5  21.91 ±  0.56  39.48 ±  1.54  137 ±  16  0.78 ±  0.05 
12  35  1.0  1.5  5.99 ±  0.32  3.21 ±  0.38  227 ±  48  1.57 ±  0.15 
a Experimental data are expressed as mean ±  SD (n = 3). 
2.1.1. Pressure Effect 
To evaluate the effect of pressure on the characteristics of the nanoparticles, experiments were 
carried out changing the pressure from 8 MPa to 15 MPa. The effect of pressure on morphology and 
mean particle size of nanoparticles was illustrated in Figure 1A–D and Table 1, respectively. One 
pattern of the particle size distribution was shown in Figure 2. It was noticed that at pressure of 10 MPa, Int. J. Mol. Sci. 2012, 13  6457 
 
 
12 MPa and 15 MPa, the morphology of nanoparticles exhibited spherical shape with smooth surface, 
while at the pressure of 8 MPa, the morphology became irregular. Nanoparticles could be produced 
when the pressure was well above the mixture critical point (MCP). In the CO2-DMSO-acetone system, 
the MCP of this system is above 8 MPa as described previously [24]. The experimental condition of 8 
MPa was located in the two-phase region, which might be a reason that the nanoparticles could not be 
formed. However, the experimental conditions of 10 MPa, 12 MPa and 15 Mpa were located in the 
supercritical region and were far above the MCP pressure, so the nanoparticles with spherical shape 
could be formed. Additionally, the particle size was decreased with a pressure increase from 10 MPa to 
15 MPa. This could be explained in terms of the volumetric expansion of the liquid phase [25]. With 
increasing  the  pressure  at  a  fixed  temperature,  the  solubility  of  mixed  solvent  in  
the  CO2  will  increase  [24].  More  CO2  will  diffuse  into  the  mixed  solvent,  thus  causing  higher 
supersaturation ratio of the expanded liquid solution, which subsequently resulted in the formation of 
smaller particles.  From  Table 1, it could  be found that the higher pressure favored lower 5-ASA 
loading and higher entrapment efficiency. The solubility of 5-ASA in mixed solvents of supercritical 
CO2 (scCO2) + acetone + DMSO was increased as the solvent power of the scCO2 was raised with 
increasing pressure at a fixed temperature [26]. Then, less 5-ASA precipitated, causing lower 5-ASA 
loading. And more 5-ASA on the surface of samples might be dissolved in the scCO2 and be taken 
away, then resulting in higher entrapment efficiency. 
Figure 1. SEM images of nanoparticles prepared by SEDS process with different pressures. 
   
A 8 MPa, 35 ° C, 1.0 mg/mL, 1.0 mL/min  B 10 MPa, 35 ° C, 1.0 mg/mL, 1.0 mL/min 
   
C 12 MPa, 35 ° C, 1.0 mg/mL, 1.0 mL/min  D 15 MPa, 35 ° C, 1.0 mg/mL, 1.0 mL/min Int. J. Mol. Sci. 2012, 13  6458 
 
 
Figure 2. Particle size distribution of nanoparticles (12 MPa, 35 °C , 1.0 mg/mL, 1.0 mL/min). 
 
2.1.2. Temperature Effect 
As shown in Figures 1C and 3A and Table 1, the morphology of nanoparticles changed from the 
spherical shape with smooth surface at 35 °C  to irregular surface at 40 °C , despite the fact that the 
mean particle size of nanoparticles increased a little. Moreover, when the temperature increased to  
45 °C , the aggregation was serious, as shown in Figure 3B. This might be due to more polymer 
plasticization effect of  CO2  [27]. Bleich  et  al.  [28] reported that the  particles  produced at  higher 
temperatures lead to compact agglomerates by bridging. 5-ASA loading was found decreased with 
increasing temperature. From the point view of thermodynamics, in the SAS process, if the solvent 
could not be completely miscible with the scCO2, two fluid phases would be formed and the solute 
would still be dissolved or partly dissolved in the liquid-rich phase [29]. It might be easier for scCO2 
and the organic solvents to form one phase at the lower temperature of 35 °C  and 40 °C . In that case, 
the higher solvent  power of scCO2 would extensively decrease solubility  of 5-ASA in  the mixed 
solvents, leading to more 5-ASA precipitated. The entrapment efficiency was found decreased with 
higher temperature, which might due to more 5-ASA would still be attached on the surface of the 
nanoparticles as the solubility of 5-ASA was decreased in scCO2.  
Figure 3. SEM images of nanoparticles prepared by SEDS process with different temperatures. 
   
A 12 MPa, 40 ° C, 1.0 mg/mL, 1.0 mL/min  B 12 MPa, 45 ° C, 1.0 mg/mL, 1.0 mL/min 
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2.1.3. Effect of 5-ASA Concentration 
From the Figures 1C and 4A,B and Table 1, it could be concluded that the lower concentration of  
5-ASA was beneficial for spherical shape and smaller particle size of nanoparticles. This phenomenon 
has  been  explained  in  terms  of  nucleation  and  growth  processes  [30,31].  In  the  case  of  lower 
concentration,  saturation  and  then  precipitation  of  the  drug  occur  very  late  during  the  droplet 
expansion process. Therefore, nucleation is the prevailing mechanism, producing smaller particles.  
5-ASA loading increased because of sufficient quantities of 5-ASA precipitated with increasing the 
concentration of 5-ASA. Entrapment efficiency decreased with the higher concentration of 5-ASA, 
which might be attributed to, at a higher concentration of the drug, the amount of polymer not being 
sufficient to effectively encapsulate the drug [32,33]. 
Figure 4. SEM images of nanoparticles prepared by SEDS process with different 5-ASA 
concentrations. 
   
A 12 MPa, 35 ° C, 0.5 mg/mL, 1.0 mL/min  B 12 MPa, 35 ° C, 1.3 mg/mL, 1.0 mL/min 
2.1.4. Effect of Solution Flow Rate 
As shown in Figures 1C and 5A,B, when the solution flow rate increased from 0.5 mL/min to  
1.5 mL/min, the morphology of the nanoparticles became aggregated, particularity at the flow rate of 
1.5 mL/min. It was also known from the Table 1 that the mean particle size of nanoparticles increased 
with an increase of solution flow rate, and the solution flow rate significantly affected the drug loading 
and entrapment efficiency. These facts might be related to hydrodynamics aspects. With an increase of 
the solution flow rate, the kinetic energy per unit mass of liquid gaining from scCO2 is decreased, 
which  decreases  the  interaction  of  antisolvent  and  solution,  hence  leading  to  the  change  of  the 
morphology, size of particles, 5-ASA loading and entrapment efficiency [25,34]. 
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Figure 5. SEM images of nanoparticles prepared by SEDS process with different solution flow rates. 
   
A 12 MPa, 35 ° C, 1.0 mg/mL, 0.5 mL/min  B 12 MPa, 35 ° C, 1.0 mg/mL, 1.5 mL/min 
2.2. Physicochemical Properties of Nanoparticles 
2.2.1. XRD Analysis 
The XRD analysis was performed to investigate the crystalline structure change of nanoparticles 
after SEDS process. The XRD patterns of 5-ASA, EU S100, physical mixture of 5-ASA and EU S100, 
and 5-ASA/EU S100 nanoparticles were shown in Figure 6. The physical mixture was prepared by 
mixing 5-ASA and EU S100 directly, in which the content of 5-ASA was the same as that of nanoparticles 
(7.2%, w/w). As shown in Figure 6, the diffraction angels of 2θ = 7.54° , 15.12° , 16.5° , 30.52 ° C can be 
regarded as the feature crystalline peaks of 5-ASA. It could be seen that the pattern of the physical 
mixture was simply a superimposition of the patterns of the two raw materials, while the pattern of 
nanoparticles was significantly different from that of the physical mixture, i.e., only one diffraction 
peak of 5-ASA at 7.54°  was present, which implies a reduction in crystallinity of the treated 5-ASA as 
a result of SEDS processing. Reverchon et al. [35] suggested that the very fast precipitation process in 
supercritical conditions does not allow the organization of the compound in a regular crystalline form. 
This is also consistent with the results reported by Zu et al. [18]. 
Figure 6. XRD patterns of 5-ASA, EU S100, physical mixture and nanoparticles (12 MPa, 
35 ° C, 1.0 mg/mL, 1.0 mL/min). 
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Figure 6. Cont. 
 
2.2.2. DSC Analysis 
The DSC technique is one of the most convenient methods for investigating the compatibility of 
polymer blends, therefore it was used to investigate thermodynamic compatibility between 5-ASA and 
EU  S100  in  their  nanoparticles  based  on  crystalline  melting  temperature  and  the  glass  transition 
temperature. Figure 7 depicted the  DSC thermograms  of  above samples.  In the Eu S100, a  glass 
transition temperature region and an exothermic peak located at 243.8 ° C were observed. The raw  
5-ASA showed a sharp endothermic peak at 277.5 ° C that corresponded to its melting point, indicating 
its crystalline nature. A physical mixture of the drug with polymer resulted in the disappearance of 
such a fusion peak, replaced by broad endothermic signals exhibiting a reduced melting endotherm in 
the range of 250 ° C to 280 ° C. The presence of endothermic signals in the physical mixture confirmed 
that 5-ASA crystals still exist in physical mixture [36,37]. This type of interaction was previously 
observed  in  the  physical  mixture  of  piroxicam  with  Eu  S100  and  diflunisal  with  Eudragit  
RL 100 [37,38].  However,  for  nanoparticles,  the  intensity  of  melting  peak  of  5-ASA  disappeared 
completely.  The  disappearance  of  the  drug  endothermic  peak  in  the  nanoparticles  suggested  that  
5-ASA might be imbedded into EU S100 and existed in an amorphous state in the nanoparticles, 
indicating a thermodynamic compatibility between 5-ASA and EU S100 [26]. 
2.2.3. FTIR Spectroscopy Analysis 
The FTIR spectroscopy analysis was used to obtain information on the change of chemical structure 
after  SEDS  processing,  and  the  FTIR  spectra  of  above  samples  were  shown  in  Figure  8.  Some 
characteristic functional group and wavenumber were summarized in Table 2. In the FTIR spectra of 
EU S100, the C=O vibration band of the carboxylic groups presented as a shoulder at 1705 cm
−1; 
whereas the peak at 1730 cm
−1 was attributed to the esterified carboxyl groups [38]. The characteristic 
peaks of 5-ASA spectra had been already described by Mladenovska et al. [39], and they corresponded 
to: 3445 cm
−1 (mutual overlapping of νNH and νOH stretching), 1650 cm
−1 (C=O stretch), 1620 cm
−1 
(NH blend), 1356 cm
−1 (C–N stretch), 2000–3000 cm
−1 (stretching vibrations of the hydrogen bonds). 
The FTIR spectra of physical mixture and nanoparticles were similar to the EU S100 spectra, except 
for the 5-ASA peak of C–N located at 1356 cm
−1 and C=O located at 1650 cm
−1. The reason might be 
that the amount of 5-ASA in both physical mixture and nanoparticles was relatively low, resulting in Int. J. Mol. Sci. 2012, 13  6462 
 
 
the most characteristic peaks of 5-ASA occurred covered by broad peak from EU S100 in this region. 
The FTIR spectra between physical mixture and nanoparticles didn’t show any significant differences, 
indicating the molecular structure of processed nanoparticles has no change, as confirmed by HPLC 
analysis (data not shown). 
Figure  7.  DSC  thermograms  of  5-ASA,  EU  S100,  physical  mixture  and  nanoparticles  
(12 MPa, 35 ° C, 1.0 mg/mL, 1.0 mL/min). 
 
Figure 8. FTIR spectra of 5-ASA, EU S100, physical mixture and nanoparticles (12 MPa, 
35 ° C, 1.0 mg/mL, 1.0 mL/min). 
 Int. J. Mol. Sci. 2012, 13  6463 
 
 
Table 2. Shows wavenumber (cm
−1) and functional group for 5-ASA, Eu S100, physical 
mixture and nanoparticles (12 MPa, 35 ° C, 1.0 mg/mL, 1.0 mL/min) using FTIR. 
Eu S100 
 
5-ASA 
 
Physical mixture 
 
Nanoparticles 
Wavenumber  Functional  
 
Wavenumber  Functional  
 
Wavenumber  Functional  
 
Wavenumber  Functional  
(cm
−1)  group 
 
(cm
−1)  group 
 
(cm
−1)  group 
 
(cm
−1)  group 
3438  O–H 
 
3445  N–H 
 
3438  O–H 
 
3438  O–H 
1705  C=O 
 
3445  O–H 
 
1705  C=O 
 
1705  C=O 
1730  C=O 
 
1650  C=0 
 
1730  C=O 
 
1730  C=O 
     
1620  N–H 
 
1650  C=0 
 
1650  C=0 
     
1356  C–N 
 
1356  C–N 
 
1356  C–N 
3. Experimental Section 
3.1. Materials 
5-ASA (98% purity) was purchased from Shanghai Chemical Reagent Plant (Shanghai, China). EU 
S100 polymer was kindly donated from Evonik Pharma Polymers (Darmstadt, Germany). CO2 (99.95% 
purity)  was  obtained  from  SJTU  Chemical  Store  (Shanghai,  China).  Acetone  (≥99.5%  purity), 
Dimethyl  sulfoxide  (DMSO,  98.5%  purity)  were  purchased  from  Shanghai  Lingfeng  Chemical 
Reagent Co., Ltd. (Shanghai, China). All solutions used in HPLC analysis were of HPLC grade and 
filtered using a 0.22 µm membrane filter with a filtration system (SHB-III, China). 
3.2. Experimental Apparatus and Procedure 
The experimental apparatus was purchased from Nantong Huaxing Petroleum Devices Co. Ltd. 
(Jiangsu, China). The technical details of the SEDS process in this study had already been described in 
our  previous  work  [25,28].  Briefly,  scCO2  and  organic  solution  were  separately  pumped  into  a  
high-pressure vessel (200 mL) through different inlets of a coaxial nozzle. The coaxial nozzle was 
located on the top of the high-pressure vessel, with an inner tubule (diameter is 0.2 mm) and an outer 
tubule (diameter is 1 mm). A rapid mutual mixing diffusion at the outlet interface of scCO2 and the 
organic solution occurred instantaneously. Meanwhile, solutes dissolved originally in organic solvent 
reached its supersaturation in very short time, resulting in the formation of solid nanoparticles in the 
vessel. Once feeding the solution finished, the scCO2 was continuously pumped for about 45 min in 
order to remove the residual organic solvent of the samples. Finally, the vessel was slowly depressurized 
to the atmospheric pressure and the samples were collected for further characterization.  
3.3. Preparation Conditions of 5-ASA/EU S100 Nanoparticles 
The experimental conditions were designed as shown in Table 1. In all trials, the mixed organic 
solvents of acetone and DMSO (7:3, v/v) were used for dissolving 5-ASA and EU S100, in which the 
EU S100 concentration was fixed at 4.0 mg/mL, the flow rate of scCO2 was maintained at 3 kg/h. The 
process parameters studied were varied in the range as presented in Table 1 to determine their effects 
on characteristics of nanoparticles precipitated. In our study, only one process parameter was varied 
according to the range specified while other operating conditions were kept unchanged. 
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3.4. Nanoparticle Characterization 
3.4.1. SEM Analysis 
The surface morphology of the processed samples was observed by SEM (JEOL, JSM-7401F, Japan). 
In the analysis, the samples were firstly attached to a small piece of electro-conductive paste silicon 
chip,  then  sputter-coated  with  Au  using  an  LDM-1500  vacuum  sputter  coater  (Shanghai  Electron 
Optical Tech, Academe PR China). 
3.4.2. Particle Size and Particle Size Distribution Analysis  
The particle size and particle size distribution were analyzed by a laser particle size analyzer (ZS90, 
Malvern, UK). Before measurement, a small amount of nanoparticles were suspended in distilled water, 
the suspension was then dispersed by ultrasonic waves with power 120 W for 1 min. Particle size and 
particle size distribution were then assayed by the analytic software. The measurement was performed in 
triplicate. PSD is expressed by span, which can be calculated according to the following Equation: 
0.9 0.1
0.5
Span
dd
d


 
(1) 
where d0.1, d0.5, and d0.9 are the volumes occupied by particles 10% undersize diameter, mean size 
diameter, and 90% undersize diameter, respectively. 
3.4.3. 5-ASA Loading and Entrapment Efficiency Measurement 
The  content  of  5-ASA  was  measured  by  HPLC  (Agilent  1100  Series  HPLC  system,  Agilent 
Technologies Shanghai, China). Agilent Eclipse XDB-C18 4.6 mm ×  250 mm ×  5 μm column was 
used and an ultraviolet detector was set at 240 nm. The mobile phase consisted of mobile phase A 
(dissolving and diluting tetrabutylammonium hydrogen sulfate 3.4 g, sodium acetate 1.4 g to 1000 mL 
with purified water, then adjusting with 1 M sodium hydroxide to a pH of 6.6) and mobile phase B 
(acetonitrile) (77:23 v/v). The volumetric flow was 1.0 mL/min and the temperature of column was 
maintained at 25 ° C. 
The 5-ASA loading was defined as the content of 5-ASA in the nanoparticles. The measurement 
method was as follows: a known quantity of nanoparticles was weighed, and then dissolved in 0.1 M 
phosphate-buffered saline (PBS, pH 7.4), in which the amount of 5-ASA was determined as described 
above in triplicate. Entrapment efficiency was defined as the amount of 5-ASA entrapped inside the 
nanoparticles and measured as follows: a certain amount of the nanoparticles was firstly dispersed in  
3 mL HCL (0.1 M, pH 1.2) and vortexed for 1 min, and then centrifuged at 13,000×  g for 3 min. The 
supernatant was collected and the precipitate was redispersed with 3 mL HCL. The same step was 
repeated three times to make sure that the 5-ASA attached on the surface was all collected. The amount 
of 5-ASA in the total collected solution was determined as given above in triplicate. The equations of the 
5-ASA loading and entrapment efficiency were calculated by Equations 2 and 3, respectively. 
 
Total amount of 5-ASA in nanoparticles
5-ASA loading  % 100
Total amount of nanoparticles
   (2) Int. J. Mol. Sci. 2012, 13  6465 
 
 
 
Total amount of 5-ASA in nanoparticles Amount 
of 5-ASA on the surface of nanoparticles
Entrapment efficiency  %   100
Total amount of 5 ASA in nanoparticles



  (3) 
3.4.4. XRD Analysis  
The  crystalline  characters  of  5-ASA,  EU  S100,  physical  mixture  of  5-ASA  and  EU  S100,  and  
5-ASA/EU S100 nanoparticles were analyzed by XRD (D/max-2200/PC, Japan Rigaku Corporation, 
Japan)  with  a  rotating  Cu  anode.  The  Cu  Ka  radiation  was  generated  at  20  mA  and  40  kV  and 
monochromatized by a nickel filter. Diffraction patterns recorded the X-ray intensity as a function of 
2θ angle covering from 2.0° to 50.0°. The scanning rate was 6°/min. 
3.4.5. DSC Analysis 
DSC  (Pyris  1,  Perkin  Elmer,  Inc.,  USA)  was  used  to  investigate  the  thermal  behaviors  of  the 
samples above. 5-mg samples were placed in aluminum pans and sealed. The probes were heated from 
40 ° C to 300 ° C at a rate of 10 ° C/min under nitrogen atmosphere. 
3.4.6. FTIR Spectroscopy Analysis 
FTIR (Spectrum 100, Perkin Elmer, Inc., USA) spectroscopy analysis was used to obtain information 
on the change of chemical structure of samples above. The sample powder was dispersed in KBr powder 
and this mixture was pressed into a pellet for scanning in the infrared range of 500–4000 cm
−1.  
4. Conclusions  
In the present work, a process for preparation of 5-ASA loaded Eu S100 nanoparticles by SEDS 
technique has been developed. The influences of various process parameters on morphology, particle 
size, 5-ASA loading and entrapment efficiency were systematically investigated. The morphology and 
particle size of the nanoparticles could be adjusted by modifying various process parameters, such as 
pressure, temperature, 5-ASA concentration and solution flow rate. With the appropriate parameters, 
nanoparticles with spherical shape and smaller particle size could be obtained. The lower temperature, 
5-ASA concentration and solution flow rate coupled with higher pressure favored smaller and more 
regular spherical nanoparticles. The 5-ASA loading and entrapment efficiency were also dependent on 
different process parameters and it was found that the solution flow rate significantly affect the drug 
loading and entrapment efficiency. The XRD and DSC analyses revealed that 5-ASA was imbedded 
into EU S100 and existed in an amorphous state in the nanoparticles. FTIR analysis showed that the 
SEDS process did not induce degradation of 5-ASA. These results collectively indicate that the SEDS 
technique is a simple and effective process for preparing nanoparticles. 
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